A potential treatment from Insys Therapeutics Inc. for an aggressive form of brain cancer will have some marketing exclusivity if regulators eventually approve it. The Food and Drug Administration has granted an orphan drug designation to the Chandler, Arizona, drugmaker's pharmaceutical cannabidiol, or CBD.
Pfizer and Merck announced today that they have entered into an agreement to explore the therapeutic potential of the combination of Pfizer’s crizotinib with Merck’s investigational anti-PD-1 antibody pembrolizumab, in a Phase 1b clinical study evaluating the safety and tolerability of the combination in patients with ALK-positive advanced or metastatic non-small cell lung cancer.
EMD Millipore Expands Biomanufacturing Sciences and Training Center in Japan and Opens New Location in TokyoAugust 26, 2014 8:14 am | News | Comments
EMD Millipore today announced the opening of a new Biomanufacturing Sciences Training Center (BSTC) facility in Tokyo. The facility is designed to help biopharmaceutical companies develop manufacturing processes and find solutions to processing challenges in collaboration with engineers from EMD Millipore.
Biogen Idec announced that Donald R. Johns, M.D., has joined the company as vice president, leading Biogen Idec’s amyotrophic lateral sclerosis (ALS) Innovation Hub (ALS iHub).
Dr. Tom Frieden, director of the Centers for Disease Control and Prevention, is scheduled to visit Liberia, Sierra Leone and Guine. A CDC spokesman Friday said Frieden wants to meet the African and international health leaders trying to control the outbreak, and to hear what help they need.
An Oklahoma oral surgeon whose filthy clinic conditions led to the testing of thousands of patients for HIV and hepatitis permanently surrendered his professional license on Friday. Scott Harrington's two Tulsa-area clinics have been closed since March 2013, when state health officials urged about 7,000 of his current and former patients to get tested for the diseases.
Taxes? Who wants to think about taxes around Labor Day? But if you count on your tax refund and you're one of the millions getting tax credits to help pay health insurance premiums under President Barack Obama's law, it's not too early.
Alkermes Submits New Drug Application to FDA for Aripiprazole Lauroxil for Treatment of SchizophreniaAugust 25, 2014 8:44 am | News | Comments
Alkermes today announced that it has submitted a New Drug Application to the FDA for approval of aripiprazole lauroxil, the company’s investigational, novel, once-monthly, long-acting injectable atypical antipsychotic for the treatment of schizophrenia.
Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has acquired Covagen AG, a privately-held, biopharmaceutical company specializing in the development of multispecific protein therapeutics through the FynomAb technology platform.
NeuroSigma today announced that the U.S. Department of the Army, through the U.S. Army Medical Research and Material Command, has funded a Phase II clinical trial at the University of California, Los Angeles, that will examine the use of external trigeminal nerve stimulation (eTNS) as treatment for post-traumatic stress disorder (PTSD).
VIVUS today announced the acquisition of a group of patents from Janssen Pharmaceuticals, Inc. covering uses of topiramate as monotherapy and in combination with other pharmaceutical agents to treat a variety of medical conditions.
Iroko Pharmaceuticals, LLC, announced today the United States Food and Drug Administration (FDA) has approved ZORVOLEX (diclofenac) capsules, a nonsteroidal anti-inflammatory drug (NSAID), for the management of osteoarthritis pain.
Japan said Monday it is ready to provide a Japanese-developed anti-influenza drug as a possible treatment for the rapidly expanding Ebola outbreak. Chief Cabinet Secretary Yoshihide Suga said that Japan can offer favipiravir, developed by a subsidiary of Fujifilm Holdings Corp., at any time at the request of the World Health Organization.
Roche said Sunday it has reached an $8.3 billion deal to buy InterMune Inc., a California-based developer of treatments for lung diseases.
Allergan Inc. is reviewing shareholder requests for a special meeting to consider replacing most of its board, a change fellow drugmaker Valeant Pharmaceuticals International Inc. is seeking as part of the hostile takeover attempt it's been waging since April. Allergan has repeatedly...